آخر تحديث :
19/11/2024
مضاد للقىء   Ondansetron hydrochloride  
حقن
عن طريق الفم
الاستقرار في حلول استقرار مخاليط العوامل التي تؤثر على الاستقرار التوافق طريقة التعاطي مراجع pdf
   التركيب الكيميائي  

حجز الاسم التجاري   حجز الاسم التجاري     

تحذير الأسماء التجاريه المختلفه قد تحتوي علي محتوي إضافات مختلفة حسب الدوله و المعمل

Amal المكسيك
Ansentron البرازيل
Antivon المكسيك, تشيلي
Atossa بولندا
Avessaron بلجيكا
Axisetron ألمانيا
Bryterol الإكوادور, كولومبيا
Cellondan ألمانيا
Chemoset المغرب
Danac المكسيك
Danofran مصر
Danset مصر
Dantron المغرب, جمهورية جنوب أفريقيا
Dasentron الأرجنتين, العربية السعودية
Dismolan الأرجنتين, فنزويلا
Donset الهند
Emeset الهند, تركيا, رومانيا
Emetron بولندا, هنغاريا
Emistop المكسيك, بيرو
Indansen المكسيك
Nausetron جمهورية جنوب أفريقيا
Ondansan النمسا
Ondatron ألمانيا
Setronon كرواتيا
Vomiz جمهورية جنوب أفريقيا
Yatrox إسبانيا
Zofer تركيا
Zofran ألمانيا, أيسلندا, إيطاليا, الأرجنتين, الإكوادور, الإمارات العربية المتحدة, البرتغال, الدنمارك, السويد, العربية السعودية, المغرب, النرويج, النمسا, الولايات المتحدة, ايرلندا, بريطانيا العظمي, بلجيكا, بولندا, بيرو, تركيا, زيلاندا الجديدة, سويسرا, فنلندا, كندا, كولومبيا, لوكسمبورغ, ماليزيا, مصر, هنغاريا, هولندا
Zofron يونان
Zontron تركيا
Zophren تونس, فرنسا
Zotrix السويد
مراجع   حقن   مراجع : Ondansetron hydrochloride  
نوع منشور
3 مجلة Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
6 مجلة Trissel LA, Xu QA, Martinez JF, Fox JL.
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C.
Am J Hosp Pharm 1994 ; 51: 2138-2142.
16 مجلة Chung KC, Moon YSK, Chin A, Ulrich WU, Gill MA.
Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1554-1556.
18 مجلة Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA.
Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 391-394.
23 مجلة Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP.
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection.
Am J Health-Syst Pharm 1997 ; 54: 1065-1068.
25 مجلة McGuire TR, Narducci WA, Fox JL.
Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions.
Am J Hosp Pharm 1993 ; 50: 1410-1414.
26 مجلة Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
30 مجلة Hagan RL, Mallett MS, Fox JL.
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days.
Am J Health-Syst Pharm 1996 ; 53: 1431-1435.
36 مجلة Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
47 مجلة Burm JP, Jhee SS, Chin A, Moon YSK.
Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration.
Am J Hosp Pharm 1994 ; 51: 1201-1204.
50 مجلة Fleming RA, Olsen DJ, Savage PD, Fox JL.
Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions.
Am J Health-Syst Pharm 1995 ; 52: 514-516.
52 مجلة Kirkham JC, Rutherford ET, Cumingham GN, Daneshmand KA, Falls AL.
Stability of ondansetron hydrochloride in a total parenteral nutrient admixture.
Am J Health-Syst Pharm 1995 ; 52: 1557-1558.
53 مجلة Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD.
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
59 مجلة Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81 مجلة Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 مجلة Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
91 مجلة Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
93 مجلة Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99 مجلة Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
113 مجلة Jhee SS, Jeong EW, Chin A, Inagaki K, Fox JL, Gill MA.
Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C.
Am J Hosp Pharm 1993 ; 50: 1918-1920.
132 مجلة Najari Z, Rusho WJ.
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Am J Health-Syst Pharm 1997 ; 54: 181-184.
150 مجلة Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
169 مجلة Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
179 مجلة Stiles ML, Allen LV Jr, Fox JL.
Stability of ondansetron hydrochloride in portable infusion-pump reservoirs.
Am J Hosp Pharm 1992 ; 49: 1471-1473.
183 مجلة Bosso JA, Prince RA, Fox JL.
Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C.
Am J Hosp Pharm 1992 ; 49: 2223-2225.
184 مجلة Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 مجلة Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 مجلة Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 مجلة Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 مجلة Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
266 مجلة Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299 مجلة Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301 مجلة Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 مجلة Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
332 مجلة Xu QA, Trissel LA, Fox JL.
Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration.
Ann Pharmacotherapy 1995 ; 29: 1106-1109.
333 مجلة Graham CL, Dukes GE, Kao CF, Bertch JM, Hak LJ.
Stability of ondansetron in large-volume parenteral solutions.
Ann Pharmacotherapy 1992 ; 26: 768-771.
334 مجلة Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 مجلة Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
492 مجلة Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
815 مجلة Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905 مجلة Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
915 مجلة Casto DT.
Stability of ondansetron stored in polypropylene syringes.
Ann Pharmacotherapy 1994 ; 28: 712-714.
917 مجلة Blaise N, Vigneron J, Perrin A, Noirez V, Hoffman MA, Hoffman M.
Stability of refrigerated and frozen solutions of ondansetron hydrochloride.
EJHP 1994 ; 4: 12-13.
921 مجلة Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
969 مجلة Jarosinski PF, Hirschfeld S.
Precipitation of ondansetron in alkaline solutions.
N Engl J Med 1991 ; 325: 1315-1316.
979 مجلة D'Arcy PF.
In vitro compatibility of granisetron with selected alkaline drugs.
Int Pharm J 1995 ; 9: 57.
992 مجلة Beijnen JH, Koks CHW.
Visual compatibility of ondansetron and dexamethasone.
Ann Pharmacotherapy 1991 ; 25: 869.
1026 مجلة Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1396 مجلة Hauser AR, Trissel LA, Martinez JF.
Ondansetron compatible with sodium acetate.
J Clin Oncol 1993 ; 11: 197.
1410 مجلة Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 مجلة Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 مجلة Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 مجلة Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 مجلة Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 مجلة Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1699 مجلة Plaas S, Heck C, Kubrich M.
Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin.
Krankenhauspharmazie 2000 ; 21: 107-109.
1712 مجلة Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1721 مجلة Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 مجلة Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1800 مجلة Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803 مجلة Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1868 مجلة Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D.
Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange.
Nutr Clin Metab 2003 ; 17: 8-14.
1925 مجلة Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 مجلة Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2002 مجلة Abanmy NO, Zaghloul IY, Radwan MA.
Compatibility of tramadol hydrochloride injection with selected drugs and solutions.
Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2012 مجلة Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M.
Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.
Am J Health-Syst Pharm 2005 ; 62: 2001-2005.
2108 مجلة Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2202 مجلة Acin Lazaro MP, bono Arino C, martinez Bazan R, manzanares Marin I, Faci Bouthelier A, Velamazan Blocona MJ, Facorro Gaspar E,
Estabilidad de parecoxib en dilucion con ostros farmacos y administrado en perfusion continua IV para el control del dolor postoperatorio.
Investig Clin Farm 2005 ; 2, 4: 195-203.
2233 مجلة Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2261 مجلة Fernandez C, Pelloquin A, Berthoume M, Bellanger A, Farinotti R.
Stabilité et compatibilité de l'association ondansétron-méthylprednisolone en solution.
Can J Hosp Pharm 2008 ; 61, 3: 191-195.
2262 مجلة Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 مجلة Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2328 مختبر Sugammadex (Bridion®) – Résumé des caractéristiques du produits
Organon 2009
2841 مجلة Gonzalves Navaro M, Carril Aviles M, Borras Almenar C, Romero Crespo I, Jimenez Torres NV.
Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%.
Atencion Pharmaceutica 2009 ; 11, 3: 161-166.
3012 مجلة Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3174 مجلة Rolin C, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM.
Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration.
Ann Pharmacotherapy 2011 ; 45: 130-131.
3249 مجلة Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 مجلة Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408 مجلة Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3459 مجلة Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3474 مختبر Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3571 مجلة Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3574 مختبر Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3595 مختبر Aciclovir - Summary of Product Characteristics
Hospira 2009
3728 مجلة Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791 الملصق Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3824 مجلة Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 الملصق Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 الملصق Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 الملصق So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3925 مجلة Simar J, Godet M, Hecq J.-D, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L.
Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C.
Ann Pharm Fr 2016 ; 75, 1 : 30-39.
3948 مجلة Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
3964 مجلة Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3967 مجلة Staven V, Herra I, Wang S, Grönlie I,Tho I.
Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.
J Pharm Pharmacol 2017 ;69,7:448-462
3976 مجلة Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3981 مجلة He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D.
Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study
EJHP 2017 ;24:162?166
4036 مجلة Estan-Cerezo G, Matoses-Chirivella C, Soriano-Iriga L, Murcia-Lopez A.C, Rodrguez-Lucena F.J, Navarro-Ruiz A.
Stability and compatibility of ondansetron with haloperidol in parenteral admixtures.
EJHP 2017 ;25,4: 200-203.
4055 مجلة Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4082 مجلة Espinosa-Bosch M, Sanchez-Rojas F, Bosche-Ojeda C.
Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures.
EJHP 2018 ; 25, e2
4116 مجلة Chen F, Zhu J, Li B, Yuan F, Wang K.
Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems.
Drug Design Dev Ther 2016 ;10:1869-1875
4145 مجلة Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 مجلة Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 مجلة Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4429 مجلة Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H.
Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration.
Medicine 2016 ; 95:25(e3824)
4433 مجلة Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4479 مجلة Closset M, Goderniaux N, Colsoul M-L, Soumoy L, Bihin B, Jamart J, Odou P, Hecq J-D, galanti L.
Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5 +/- 3°C.
J Oncol Pharm Practice 2020 ;27,6:1328-1332
4507 مجلة Ross E, Salinas A, Petty K, Her C, Carpenter J.
Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4521 مجلة Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
4528 مجلة Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4579 مجلة Tomczak S, Radwan V, Jelinska A, Stawny M.
Application of the HPLC Method in Parenteral Nutrition Assessment: Stability Studies of Ondansetron
Processes 2021 , 9, 453.
4650 مختبر Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4666 مجلة Lee C.H, Kim A.R, Lee M.K, Oh J.S, Lee D.K, Choi S.S.
Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron.
J Anal Sci Tech 2020 ; 11: 32.
4742 مجلة Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.
4776 مجلة Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A.
Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures.
Pharmaceutics 2023 ; 15: 2143.
4801 مجلة Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales